VII. International Conference on Malignant Lymphoma
2–5 June 1999 – Lugano, Switzerland

Acknowledgements
Committees vi
Financial Support vi

Summary of Conference Schedule vii
Conference Schedule ix

Abstracts
Opening Ceremony 1
Henry Kaplan Memorial Lecture 1

Oral Presentations
002–006 1. Virology 2
007–014 2. Lymphoma in Transplanted and Immunodeficient Patients 4
015–019 3. Biology I 6
020–027 4. Biology II 8
028–031 5. Biology of Germinal Centers 10
032 6. Key Note Lecture I 11
033–037 7. Review Lectures 12
038–043 8. CNS Lymphoma 14
044–045 9. High Dose Chemotherapy in Multiple Myeloma 16
046–051 10. Biology III 17
052–057 11. Cutaneous Lymphoma 19
058 12. Key Note Lecture II 21
059–065 13. Clinical Results in Lymphoma I 22
066–072 14. Clinical Results in Lymphoma II 24
073–083 15. Pediatric Lymphoma 26
084–094 16. Clinical-Pathological Correlations 29
095–104 17. Vaccines and Monoclonal Antibodies 32
105–114 18. Future Developments 35

Posters
115–133 1. Epidemiology/Diagnostics/Pathology 38
134–177 2. Biology/Genetics 43
178–206 3. Aggressive Lymphoma and Pediatric Lymphoma 54
207–236 4. CLL/Indolent Lymphoma/Extranodal Lymphoma 62
237–255 5. Hodgkin’s Disease 70
256–274 6. High Dose Therapy 75

Further Abstracts
275–323 1. Epidemiology/Diagnostics/Pathology 80
324–370 2. Biology/Genetics 93
371–430 3. Aggressive Lymphomas 105
431–444 4. Pediatric Lymphomas 120
445–482 5. CLL/Indolent Lymphomas 124
483–548 6. Extranodal Lymphomas 134
549–592 7. Hodgkin’s Disease 151
593–644 8. High Dose Therapy 162
645–674 9. Miscellaneous 175

Subject Index 183
Author Index 193
Abstracts of Satellite Symposia 213
Emerging Role of Radioimmunotherapy for the Management of Non-Hodgkin's Lymphoma

WEDNESDAY
JUNE 2
1999
6:00 PM
TO
9:15 PM

Palazzo
Dei Congressi
Lugano
Room B

Program Chairman

RICHARD I. FISHER, MD
Director, Cardinal Bernardin Cancer Center
Loyola University Medical Center
Maywood, Illinois

SmithKline Beecham ONCOLOGY

Coulter PHARMACEUTICAL

The Courage to Dream, The Determination to Deliver
VII. INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

Lugano, Switzerland
2–5 June 1999


PARTICIPANTS ARE CREDITED WITH 25 POINTS ESMO-MORA CATEGORY I
# Table of Contents

Acknowledgements
Committees
Financial Support

Summary of Conference Schedule

Conference Schedule

## Abstracts

**Opening Ceremony**
001 Henry Kaplan Memorial Lecture 1

### Oral Presentations

- 002–006 1. Virology 2
- 007–014 2. Lymphoma in Transplanted and Immunodeficient Patients 4
- 015–019 3. Biology I 6
- 020–027 4. Biology II 8
- 028–031 5. Biology of Germinal Centers 10
- 032 6. Key Note Lecture I 11
- 033–037 7. Review Lectures 12
- 038–043 8. CNS Lymphoma 14
- 044–045 9. High Dose Chemotherapy in Multiple Myeloma 16
- 046–051 10. Biology III 17
- 052–057 11. Cutaneous Lymphoma 19
- 058 12. Key Note Lecture II 21
- 059–065 13. Clinical Results in Lymphoma I 22
- 066–072 14. Clinical Results in Lymphoma II 24
- 073–083 15. Pediatric Lymphoma 26
- 084–094 16. Clinical-Pathological Correlations 29
- 095–104 17. Vaccines and Monoclonal Antibodies 32
- 105–114 18. Future Developments 35

### Posters

- 115–133 1. Epidemiology/Diagnostics/Pathology 38
- 134–177 2. Biology/Genetics 43
- 178–206 3. Aggressive Lymphoma and Pediatric Lymphoma 54
- 207–236 4. CLL/Indolent Lymphoma/Extranodal Lymphoma 62
- 237–255 5. Hodgkin's Disease 70
- 256–274 6. High Dose Therapy 75

### Further Abstracts

- 275–323 1. Epidemiology/Diagnostics/Pathology 80
- 324–370 2. Biology/Genetics 93
- 371–430 3. Aggressive Lymphomas 105
- 431–444 4. Pediatric Lymphomas 120
- 445–482 5. CLL/Indolent Lymphomas 124
- 483–548 6. Extranodal Lymphomas 134
- 549–592 7. Hodgkin's Disease 151
- 593–644 8. High Dose Therapy 162
- 645–674 9. Miscellaneous 175

### Subject Index

### Author Index

### Abstracts of Satellite Symposia
## Table of Contents

### Acknowledgements
Committees \hspace{1cm} vi
Financial Support \hspace{1cm} vii

### Summary of Conference Schedule

### Conference Schedule

### Abstracts

#### Opening Ceremony

001 \hspace{1cm} Henry Kaplan Memorial Lecture \hspace{1cm} 1

#### Oral Presentations

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>002-006</td>
<td>1. Virology</td>
</tr>
<tr>
<td>007-014</td>
<td>2. Lymphoma in Transplanted and Immunodeficient Patients</td>
</tr>
<tr>
<td>015-019</td>
<td>3. Biology I</td>
</tr>
<tr>
<td>020-027</td>
<td>4. Biology II</td>
</tr>
<tr>
<td>028-031</td>
<td>5. Biology of Germinal Centers</td>
</tr>
<tr>
<td>032</td>
<td>6. Key Note Lecture I</td>
</tr>
<tr>
<td>033-037</td>
<td>7. Review Lectures</td>
</tr>
<tr>
<td>038-043</td>
<td>8. CNS Lymphoma</td>
</tr>
<tr>
<td>044-045</td>
<td>9. High Dose Chemotherapy in Multiple Myeloma</td>
</tr>
<tr>
<td>046-051</td>
<td>10. Biology III</td>
</tr>
<tr>
<td>052-057</td>
<td>11. Cutaneous Lymphoma</td>
</tr>
<tr>
<td>058</td>
<td>12. Key Note Lecture II</td>
</tr>
<tr>
<td>059-065</td>
<td>13. Clinical Results in Lymphoma I</td>
</tr>
<tr>
<td>066-072</td>
<td>14. Clinical Results in Lymphoma II</td>
</tr>
<tr>
<td>073-083</td>
<td>15. Pediatric Lymphoma</td>
</tr>
<tr>
<td>084-094</td>
<td>16. Clinical-Pathological Correlations</td>
</tr>
<tr>
<td>095-104</td>
<td>17. Vaccines and Monoclonal Antibodies</td>
</tr>
<tr>
<td>105-114</td>
<td>18. Future Developments</td>
</tr>
</tbody>
</table>

#### Posters

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>115-133</td>
<td>1. Epidemiology/Diagnostics/Pathology</td>
</tr>
<tr>
<td>134-177</td>
<td>2. Biology/Genetics</td>
</tr>
<tr>
<td>178-206</td>
<td>3. Aggressive Lymphoma and Pediatric Lymphoma</td>
</tr>
<tr>
<td>207-236</td>
<td>4. CLL/Indolent Lymphoma/Extranodal Lymphoma</td>
</tr>
<tr>
<td>237-255</td>
<td>5. Hodgkin's Disease</td>
</tr>
<tr>
<td>256-274</td>
<td>6. High Dose Therapy</td>
</tr>
<tr>
<td>275-323</td>
<td>1. Epidemiology/Diagnostics/Pathology</td>
</tr>
<tr>
<td>324-370</td>
<td>2. Biology/Genetics</td>
</tr>
<tr>
<td>371-430</td>
<td>3. Aggressive Lymphomas</td>
</tr>
<tr>
<td>431-444</td>
<td>4. Pediatric Lymphomas</td>
</tr>
<tr>
<td>445-482</td>
<td>5. CLL/Indolent Lymphomas</td>
</tr>
<tr>
<td>483-548</td>
<td>6. Extranodal Lymphomas</td>
</tr>
<tr>
<td>549-592</td>
<td>7. Hodgkin's Disease</td>
</tr>
<tr>
<td>593-644</td>
<td>8. High Dose Therapy</td>
</tr>
<tr>
<td>645-674</td>
<td>9. Miscellaneous</td>
</tr>
</tbody>
</table>

#### Further Abstracts

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>80</td>
<td>1. Epidemiology/Diagnostics/Pathology</td>
</tr>
<tr>
<td>93</td>
<td>2. Biology/Genetics</td>
</tr>
<tr>
<td>105</td>
<td>3. Aggressive Lymphomas</td>
</tr>
<tr>
<td>120</td>
<td>4. Pediatric Lymphomas</td>
</tr>
<tr>
<td>124</td>
<td>5. CLL/Indolent Lymphomas</td>
</tr>
<tr>
<td>134</td>
<td>6. Extranodal Lymphomas</td>
</tr>
<tr>
<td>151</td>
<td>7. Hodgkin's Disease</td>
</tr>
<tr>
<td>162</td>
<td>8. High Dose Therapy</td>
</tr>
<tr>
<td>175</td>
<td>9. Miscellaneous</td>
</tr>
</tbody>
</table>

### Subject Index

### Author Index

### Abstracts of Satellite Symposia

183

193

213
Acknowledgements

Committees

Conference President
F. Cavalli, Bellinzona, Switzerland

International Organizing Committee
J.O. Armitage, Omaha, USA
A. Hagenbeek, Rotterdam, The Netherlands
T.A. Lister, London, UK
J.E. Ultmann, Chicago, USA

Scientific Advisory Board
G. Bonadonna, Milan, Italy
F. Cabanillas, Houston, USA
G.P. Canellos, Boston, USA
B. Coiffier, Pierre Bénite, France
R. Dalla-Favera, New York, USA
V. Diehl, Cologne, Germany
R.I. Fisher, Maywood, USA
S.J. Kormeyer, St. Louis, USA
D.L. Longo, Baltimore, USA
F. Melchers, Basel, Switzerland
E. Montserrat, Barcelona, Spain
S.B. Murphy, Chicago, USA
P.G. Pelicci, Milan, Italy
K. Rajewsky, Cologne, Germany
S.A. Rosenberg, Stanford, USA
M. Rozencweig, Princeton, USA
H. Stein, Berlin, Germany

Local Organization and Conference Secretariat
O. Jackson, Lugano, Switzerland
Acknowledgements

Financial Support

The conference organizers wish to thank the following sponsors for their financial support:

Main Sponsors
Amgen (Europe)
Bristol-Myers Squibb
Chugai-Rhône Poulenc
Coulter Pharmaceutical
Crossair
Cure for Lymphoma Foundation, USA
Hoffmann-La Roche
Lega Ticinese Contro il Cancro
Ligand Pharmaceuticals
Lotteria dello Stato
NeXstar Pharmaceuticals
SmithKline Beecham
Schering Germany
Schering-Plough Int.
Swiss League Against Cancer
Swissair

Sponsors
Asta Medica
Eli-Lilly
Glaxo Wellcome
Municipio di Lugano
Miltenyi Biotec
Mundipharma
Novartis Pharmaceuticals
Pharmacia & Upjohn
Summary of Conference Schedule

**TUESDAY, JUNE 1, 1999**

01:30 p.m.  WORKSHOP (Teatrino)  
'Biological Prognostic Factors' (by invitation only)

**SATELLITE SYMPOSIUM**

04:30 p.m.  MABTHERA: FUTURE APPLICATIONS IN CD20+ MALIGNANCIES  
(Room A)  
Chairmen: A. Hagenbeek and R.I. Fisher

04:30 p.m.  TWO NOVEL THERAPIES FOR THE TREATMENT OF CUTANEOUS  
T-CELL LYMPHOMA (Room B)  
Chairman: C. F. LeMaistre

07:30 p.m.  MOLECULAR REMISSION OF FOLLICULAR LYMPHOMA –  
THE REALITY (Room A)  
Chairmen: T.A. Lister and F. Cavalli

07:30 p.m.  DEVELOPING ROLES FOR LIPOSOMAL THERAPIES IN MALIGNANT  
LYMPHOMA (Room B)  
Chairman: S. Amadori

**WEDNESDAY, JUNE 2, 1999**

07:30–08:45 a.m.  POSTER SET UP (Villa Ciani)

08:00–08:45 a.m.  MEET THE PROFESSOR – first part (Rooms A, B I, B III, C, Teatrino, Kursaal)

09:00–11:00 a.m.  POSTER VIEWING (Villa Ciani)

09:00–09:45 a.m.  MEET THE PROFESSOR – second part (Rooms A, B I, B III, C, Teatrino,  
Kursaal)

11:00–11:45 a.m.  POSTER DISCUSSION WITH DISCUSSION LEADERS (Rooms and  
sessions are indicated in the Pocket Program)

12:00–01:00 p.m.  LUNCH (Parco Ciani)

01:00 p.m.  OPENING OF THE CONFERENCE (Room A/B)

01:15 p.m.  AWARD OF THE SAN SALVATORE FOUNDATION (Room A/B)

01:30 p.m.  HENRY KAPLAN MEMORIAL LECTURE (Room A/B)

02:30–03:55 p.m.  SESSION 1 – VIROLOGY (Room A/B)

04:15–06:30 p.m.  SESSION 2 – LYMPHOMAS IN TRANSPLANTED AND IMMUNODEFICIENT PATIENTS (Room A/B)

**SATELLITE SYMPOSIUM**

06:30 p.m.  EMERGING ROLE OF RADIOIMMUNOTHERAPY FOR THE  
MANAGEMENT OF NON-HODGKIN’S LYMPHOMA (Room B)  
Chairman: R.I. Fisher
THURSDAY, JUNE 3, 1999

07:30–08:15 a.m.  REPETITION OF MEET THE PROFESSOR – first part
                   (Rooms A, B I, B III, C, Teatrino, Kursaal)
08:20–09:45 a.m.  SESSION 3 – BIOLOGY OF LYMPHOMA I (Room A/B)
10:00–11:55 a.m.  SESSION 4 – BIOLOGY OF LYMPHOMAS II (Room A)
10:00–11:45 a.m.  WORKSHOP I – BIOLOGY OF GERMINAL CENTERS (Room B)
12:00–12:45 p.m.  KEY NOTE LECTURE I (Room A/B)
01:00–02:30 p.m.  LUNCH (Parco Ciani)
02:30–04:10 p.m.  SESSION 5 – REVIEW LECTURES (Room A/B)
04:30–06:10 p.m.  WORKSHOP II – BIOLOGY AND TREATMENT OF CNS LYMPHOMAS
                   (Room A/B)
06:15–07:00 p.m.  CONTROVERSY – THE ROLE OF HIGH DOSE CHEMOTHERAPY IN
                   THE TREATMENT OF MULTIPLE MYELOMA (Room A/B)

SATELLITE SYMPOSIUM

07:30 p.m.  FOLLCULAR LYMPHOMA – PAST, PRESENT AND FUTURE (Room A)
            Chairmen: J.O. Armitage, A. Hagenbeek and B. Coiffier

FRIDAY, JUNE 4, 1999

07:30–08:15 a.m.  REPETITION OF MEET THE PROFESSOR – second part
                   (Rooms A, B I, B III, C, Teatrino, Kursaal)
08:30–10:10 a.m.  SESSION 6 – EPIDEMIOLOGY AND MISCELLANEOUS (Room A/B)
10:30–11:45 a.m.  WORKSHOP III – CUTANEOUS T-CELL LYMPHOMA (Room A/B)
12:00–12:45 p.m.  KEY NOTE LECTURE II (Room A/B)
01:00–02:30 p.m.  LUNCH (Parco Ciani)
02:30–04:15 p.m.  SESSION 7 – CLINICAL RESULTS IN LYMPHOMA I (Room A/B)
04:30–06:15 p.m.  SESSION 8 – CLINICAL RESULTS IN LYMPHOMA II (Room A/B)
04:00–06:45 p.m.  SESSION 9 – PEDIATRIC LYMPHOMAS (Room C)
04:00–06:45 p.m.  SESSION 10 – CLINICAL PATHOLOGICAL CORRELATIONS (Kursaal)
06:15 p.m.       BUFFET DINNER (Parco Ciani)
09:00 p.m.       THEATRE PERFORMANCE BY TEATRO PARAVENTO (Room A)

SATURDAY, JUNE 5, 1999

08:00–11:15 a.m.  SESSION 11 – VACCINES AND MONOCLONAL ANTIBODIES (Room A)
08:00–10:45 a.m.  SESSION 12 – FUTURE DEVELOPMENTS (Room B)
11:15 a.m.       CLOSE
WEDNESDAY, JUNE 2, 1999

07:30–08:45 a.m. POSTER SET UP (Villa Ciani)

08:00–08:45 a.m. MEET THE PROFESSOR (first part)
SALVAGE TREATMENTS IN HODGKIN’S DISEASE (Room A)
G.P. Canellos, Boston, USA

CUTANEOUS LYMPHOMA (Room B I)
R. Willemze, Amsterdam, The Netherlands

CNS LYMPHOMA (Room B III)
J. Blay, Lyon, France

LYMPHOCYTIC PREDOMINANT HODGKIN’S DISEASE (Room C)
V. Diehl, Cologne, Germany

VACCINES (Teatrino)
F.K. Stevenson, Southampton, UK

NEW IMAGING TECHNIQUES IN LYMPHOMA (Kursaal)
L.A. Moulopoulos, Athens, Greece

09:00–11:00 a.m. POSTER VIEWING (Villa Ciani) (Authors present – posters posted the whole day)

09:00–09:45 a.m. MEET THE PROFESSOR (second part)
T-CELL LYMPHOMA (Room A)
J.O. Armitage, Omaha, USA

GENE THERAPY (Room B I)
F.E. Cotter, London, UK

MARGINAL ZONE LYMPHOMA (Room B III)
B. Coiffier and F. Berger, Pierre-Bénite, France

LYMPHOMA IN TRANSPLANTED PATIENT (Room C)
L.J. Swinnen, Maywood, USA

BIOLOGY OF BCL-6 (Teatrino)
R. Dalla-Favera, New York, USA

MULTIPLE MYELOMA (Kursaal)
B. Barlogie, Little Rock, USA

11:00–11:45 a.m. POSTER DISCUSSION WITH DISCUSSION LEADERS
(Rooms and sessions are indicated in the Pocket Program)

12:00–01:00 p.m. LUNCH (Parco Ciani)
<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>01:00 p.m.</td>
<td>OPENING OF THE CONFERENCE (Room A/B)</td>
</tr>
<tr>
<td></td>
<td>WELCOME AND INTRODUCTORY REMARKS</td>
</tr>
<tr>
<td></td>
<td>F. Cavalli, Bellinzona, Switzerland</td>
</tr>
<tr>
<td>01:15 p.m.</td>
<td>AWARD OF THE SAN SALVATORE FOUNDATION (Room A/B) (combined with Kaplan Lecture)</td>
</tr>
<tr>
<td></td>
<td>Introduction to the Foundation: G. Ghiringhelli</td>
</tr>
<tr>
<td></td>
<td>Presentation of the Award: G. Bianchi, Chairman</td>
</tr>
<tr>
<td>01:30 p.m.</td>
<td>HENRY KAPLAN MEMORIAL LECTURE (Room A/B)</td>
</tr>
<tr>
<td></td>
<td>GASTRIC MALT LYMPHOMA: FROM CONCEPT TO CURE</td>
</tr>
<tr>
<td></td>
<td>P.G. Isaacson, London, UK</td>
</tr>
<tr>
<td>02:30–03:55 p.m.</td>
<td>SESSION 1 – VIROLOGY (Room A/B)</td>
</tr>
<tr>
<td></td>
<td>Chairman: H. Stein</td>
</tr>
<tr>
<td>02:30</td>
<td>EPSTEIN–BARR VIRUS AND LYMPHOMAGENESIS</td>
</tr>
<tr>
<td></td>
<td>A.B. Rickinson, Birmingham, UK</td>
</tr>
<tr>
<td>02:50</td>
<td>EPSTEIN–BARR VIRUS USURPS TUMOR NECROSIS FACTOR AND</td>
</tr>
<tr>
<td></td>
<td>NOTCH RECEPTOR PATHWAYS TO ALTER CELL GROWTH</td>
</tr>
<tr>
<td></td>
<td>E.D. Kieff et al., Boston, USA</td>
</tr>
<tr>
<td>03:10</td>
<td>PRESENCE OF HHV-8 IN THE BONE MARROW AND PERIPHERAL</td>
</tr>
<tr>
<td></td>
<td>BLOOD DENDRITIC CELLS OF PATIENTS WITH MULTIPLE MYELOMA</td>
</tr>
<tr>
<td></td>
<td>R. Vescio et al., Los Angeles, USA</td>
</tr>
<tr>
<td>03:25</td>
<td>EPSTEIN–BARR VIRUS PROVIDES PROLIFERATIVE ADVANTAGE TO REED–STERNBERG CELLS</td>
</tr>
<tr>
<td></td>
<td>IN CLASSICAL HODGKIN’S DISEASE AND SURVIVAL ADVANTAGE TO THE PATIENT</td>
</tr>
<tr>
<td></td>
<td>K.N. Naresh et al., Mumbai, India</td>
</tr>
<tr>
<td>03:40</td>
<td>CD81, A RECEPTOR FOR HEPATITIS C VIRUS IS A COMPONENT OF</td>
</tr>
<tr>
<td></td>
<td>A B CELL SIGNALLING COMPLEX</td>
</tr>
<tr>
<td></td>
<td>S. Levy et al., Stanford, USA</td>
</tr>
<tr>
<td>04:15–06:30 p.m.</td>
<td>SESSION 2 – LYMPHOMAS IN TRANSPLANTED AND IMMUNODEFICIENT PATIENTS (Room A/B)</td>
</tr>
<tr>
<td></td>
<td>Chairmen: U. Tirelli and M.A. Caligiuri</td>
</tr>
<tr>
<td>04:15</td>
<td>BIOLOGY OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS</td>
</tr>
<tr>
<td></td>
<td>D. Liebowitz, Philadelphia, USA</td>
</tr>
<tr>
<td>04:35</td>
<td>POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS:</td>
</tr>
<tr>
<td></td>
<td>DIAGNOSIS AND TREATMENT</td>
</tr>
<tr>
<td></td>
<td>L.J. Swinnen, Maywood, USA</td>
</tr>
<tr>
<td>04:55</td>
<td>DEVELOPING STRATEGIES FOR ADOPTIVE CELL THERAPY OF</td>
</tr>
<tr>
<td></td>
<td>TRANSPLANT RELATED EBV ASSOCIATED LYMPHOMA</td>
</tr>
<tr>
<td></td>
<td>R. O’Reilly, New York, USA</td>
</tr>
<tr>
<td>05:15</td>
<td>CHROMOSOMAL ABNORMALITIES IN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS</td>
</tr>
<tr>
<td></td>
<td>BY COMPARATIVE GENOMIC HYBRIDIZATION</td>
</tr>
<tr>
<td></td>
<td>M. Raphael et al., Bobigny, France</td>
</tr>
</tbody>
</table>
Wednesday, June 2, 1999 (continued)

05:30 011 HUMANIZED ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB) IN B POSTTRANSPLANT LYMPHOBLASTIC PROLIFERATIVE DISORDERS: A RETROSPECTIVE ANALYSIS OF 32 PATIENTS N. Milpied et al., Nantes, France

05:45 012 A RANDOMIZED STUDY OF DOSE INTENSIVE RISK ADJUSTED TREATMENT IN HUMAN IMMUNODEFICIENCY VIRUS RELATED LYMPHOMA. NHL-HIV 93 C. Gisselbrecht et al., Paris, France

06:00 013 HUMAN IMMUNODEFICIENCY VIRUS-RELATED LYMPHOMA: CORRELATIONS BETWEEN CLINICAL FEATURES AND HISTOLOGICAL SUBTYPES J. Gabarre et al., Paris, France

06:15 014 THE SPECTRUM OF CUTANEOUS LYMPHOMAS IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION: A STUDY OF 21 CASES J.P. Merlio et al., Bordeaux, France

THURSDAY, JUNE 3, 1999

07:30–08:15 a.m. MEET THE PROFESSOR (repetition first part)

08:20–09:45 a.m. SESSION 3 – BIOLOGY OF LYMPHOMAS I (Room A/B)
Chairmen: D.L. Longo and M. Fey

08:20 015 LYMPHOMA CLASSIFICATION: FROM REAL TO WHO N.L. Harris, Boston, USA

08:40 016 THE NEW CLASSIFICATION OF MALIGNANT LYMPHOMAS – CLINICAL IMPLICATIONS W. Hiddemann et al., Munich, Germany

08:55 017 MOLECULAR PATHOGENESIS OF B CELL LYMPHOMA R. Dalla-Favera, New York, USA

09:15 018 CHARACTERIZATION OF THE GENES REARRANGED IN THE t(11;18)(q21;q21) ASSOCIATED WITH MALT LYMPHOMAS J. Dierlamm et al., Hamburg, Germany

09:30 019 BCL10 GENE ABNORMALITY IN B-CELL LYMPHOMAS M.Q. Du et al., London, UK

09:45–10:00 a.m. INTERMISSION

10:00–12:00 a.m. SESSION 4 – BIOLOGY OF LYMPHOMAS II (Room A)
Chairmen: R. Dalla-Favera and J.C. Reed

10:00 020 MOLECULAR CHARACTERIZATION OF 11q DELETIONS POINTS TO A PATHOGENIC ROLE OF THE ATM GENE IN MANTLE CELL LYMPHOMA S. Stilgenbauer et al., Heidelberg, Germany
Dysregulation of Cyclin Dependent Kinase 6 (CDK6) Expression in Splenic Lymphomas Through Site Specific Chromosome 7q Translocation
D. Oscier et al., Bournemouth, UK

Antisense Oligonucleotides Directed to the BCL-2 Gene Message (G3139) with Low Dose Cyclophosphamide Cure Established Systemic Human B Cell Lymphoma in SCID Mice
R. Klasa et al., Vancouver, Canada

BCL-2 Insertion Into the IGH Locus in Follicular Lymphoma
J.W. Vandenbroucke et al., Leiden, The Netherlands

Recurrent Immunoglobulin Gene Translocations Identify Distinct Molecular Sub-Types of Myeloma
P.L. Bergsagel et al., New York, USA

Gain of Chromosome Arm 9p is Characteristic of Primary Mediastinal B-Cell Lymphomas
M. Bentz et al., Heidelberg, Germany

Recurrent Chromosome Translocations in SCID p53+/− Mice Are Mediated by V(D)J Recombinase
G.J. Vanasse et al., Seattle, USA

A T Cell Epitope Determined with Random Peptide Libraries and Combinatorial Peptide Chemistry Stimulates T Cells Specific for Cutaneous T Cell Lymphoma
T. Linnemann et al., Berlin, Germany

Workshop I – Biology of Germinal Centers (Room B)
Chairman: M. Baggioi, Co-chairman: R. Dalla-Favera

Introduction
B-Cell Traffic
M. Baggioi, Bern, Switzerland

Germinial Centre Persistence Requires T-Cell-Driven Differentiation of Centrocytes to Centroblasts
I.C.M. MacLennan et al., Birmingham, UK

An In Vitro Model for Chromosomal Translocations Driven by the V(D)J Recombinase
G. Kelsoe et al., Durham, USA

Role of BCL-6 in Germinial Center Development
R. Dalla-Favera, New York, USA

BCR Induced Death of BL60 Cells: A Model of Death of Germinial Center B-Cells
P.H. Krammer, Heidelberg, Germany

Discussion
Thursday, June 3, 1999 (continued)

12:00-12:45 a.m.  KEY NOTE LECTURE I (Room A/B)

T CELL RECEPTORS FOR CYTOKINES: A TARGET FOR IMMUNOTHERAPY
T.A. Waldmann, Bethesda, USA

01:00-02:30 p.m.  LUNCH (Parco Ciani)

02:30-04:10 p.m.  SESSION 5 – REVIEW LECTURES (Room A/B)
Chairmen: B. Coiffier and J.E. Ultmann

02:30  033  CURRENT STRATEGIES IN THE TREATMENT OF HODGKIN’S DISEASE
V. Diehl, Cologne, Germany

02:50  034  FOLLICULAR LYMPHOMA: HAVE WE MADE ANY PROGRESS?
S.J. Horning, Stanford, USA

03:10  035  DIFFUSE LARGE CELL LYMPHOMA
R.I. Fisher, Maywood, USA

03:30  036  WORKSHOP ON BIOLOGICAL PROGNOSTIC FACTORS IN AGGRESSIVE NON-HODGKIN’S LYMPHOMAS: A REPORT
M.A. Shipp, Boston, USA

03:50  037  MANTLE CELL LYMPHOMAS
W. Hiddemann, Munich, Germany

04:10-04:30 p.m.  INTERMISSION

04:30-06:10 p.m.  WORKSHOP II – BIOLOGY AND TREATMENT OF CNS LYMPHOMAS
(Room A/B)
Chairman: R. Klasa

4:30  038  AN IN VIVO PRECLINICAL MODEL TO EVALUATE AN EFFECTIVE ANTIVIRAL REGIMEN IN EPSTEIN-BARR VIRUS-ASSOCIATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
M.A. Caligiuri et al., Columbus, USA

04:50  039  PRIMARY CEREBRAL LYMPHOMAS: UNSOLVED ISSUES
J.Y. Blay, Lyon, France

05:10  040  PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: LONG TERM RESULTS OF THE GOELAMS LCP 88 TRIAL WITH A FOCUS ON NEUROLOGICAL COMPLICATIONS AMONG 152 PATIENTS
B. Desablens et al., Amiens, France

05:25  041  A PHASE 2 STUDY OF BRIEF SINGLE AGENT IV METHOTREXATE FOLLOWED BY IRRADIATION IN PRIMARY CNS LYMPHOMA
P. O’Brien et al., Newcastle, Australia

05:40  042  PRIMARY CNS LYMPHOMAS: HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS PBSCT AND HYPERFRACTIONATED RADIOTHERAPY WITHIN FIRST-LINE TREATMENT
R. Marks et al., Freiburg, Germany
Thursday, June 3, 1999 (continued)

05:55  043  INCIDENCE AND RISK FACTORS OF CENTRAL NERVOUS SYSTEM RELAPSE IN INTERMEDIATE-GRADE AND IMMUNOBlastic NON-HODGKIN'S LYMPHOMA UNIFORMLY TREATED AND RECEIVING PROPHYLAXIS FOR CNS. A GELA STUDY ON 976 PATIENTS
C. Haioun et al., Créteil, France

06:15–07:00 p.m.

THE ROLE OF HIGH DOSE CHEMOTHERAPY IN THE TREATMENT OF MULTIPLE MYELOMA – A CONTROVERSY (Room A/B)
Chairman: T.A. Lister

06:15
INTRODUCTION
T.A. Lister, London, UK

06:20  044  TANDEM TRANSPLANTS IN OVER 1000 PATIENTS WITH MULTIPLE MYELOMA – INFERIOR PROGNOSIS WITH CHROMOSOME 13 DELETION
B. Barlogie, Little Rock, USA

06:40  045  THE ROLE OF HIGH-DOSE CHEMOTHERAPY IN THE TREATMENT OF MULTIPLE MYELOMA – A CONTROVERSY
R.A. Kyle, Rochester, USA

FRIDAY, JUNE 4, 1999

07:30–08:15 a.m.

MEET THE PROFESSOR (repetition second part)

08:30–10:10 a.m.

SESSION 6 – EPIDEMIOLOGY AND MISCELLANEOUS (Room A/B)
Chairmen: P. Boyle and D. Longo

08:30  046  EPIDEMIOLOGY OF NON-HODGKIN’S LYMPHOMA: REVIEW AND RESEARCH AGENDA
S.H. Zahm et al., Rockville, USA

08:50  047  TRANSLOCATION t(14;18) IN HEALTHY INDIVIDUALS; ASSOCIATION WITH FAMILY HISTORY AND AGRICULTURAL EXPOSURE?
O. Paltiel et al., Jerusalem, Israel

09:05  048  NON-HODGKIN’S LYMPHOMA AND OCCUPATIONAL EXPOSURE TO CHEMICALS IN CANADA
J. Hu et al., Ottawa, Canada

09:20  049  DOES A T-CELL TYPE OF HODGKIN LYMPHOMA EXIST?
H. Stein et al., Berlin, Germany

09:35  050  APOPTOSIS AND CHEMOTHERAPY OF MALIGNANT TUMORS
P.H. Krammer et al., Heidelberg, Germany

09:55  051  18 FDG-PET FOR ASSESSMENT OF RESIDUAL MASSES ON CT AFTER TREATMENT OF LYMPHOMAS
N.G. Mikhaeel et al., London, UK

10:10–10:30 a.m.

INTERMISSION
WORKSHOP III – CUTANEOUS T-CELL LYMPHOMA (Room A/B)
Chairman: G. Burg

10:30 052
HISTORICAL PERSPECTIVE ON THE USE OF RETINOIDS IN CTCL
G. Burg, Zurich, Switzerland

10:40 053
EORTC CLASSIFICATION FOR PRIMARY CUTANEOUS LYMPHOMAS
R. Willemze et al., Amsterdam, The Netherlands

10:50 054
CUTANEOUS LYMPHOMAS: A PROPOSAL FOR A UNIFIED APPROACH
TO CLASSIFICATION
E.S. Jaffe, Bethesda, USA

11:00 055
CLINICAL APPROACH TO B-CELL AND T-CELL CUTANEOUS
LYMPHOMAS
R.T. Hoppe, Stanford, USA

11:15 056
A DERMATOLOGIST’S APPROACH TO THERAPY FOR CTCL
M. Duvic, Houston, USA

11:30 057
AN ONCOLOGIST’S APPROACH TO THERAPY FOR CUTANEOUS
T-CELL LYMPHOMA
F. Foss, Boston, USA

12:00–12:45 p.m.

KEY NOTE LECTURE II (Room A/B)

12:00 058
REGULATORS OF APOPTOSIS IN B-CELL NEOPLASMS
J.C. Reed, La Jolla, USA

01:00–02:30 p.m.

LUNCH (Parco Ciani)

02:30–04:15 p.m.

SESSION 7 – CLINICAL RESULTS IN LYMPHOMA I (Room A/B)
Chairmen: S.A. Rosenberg and G.P. Canellos

02:30 059
FOURTEEN YEARS CLINICAL TRIAL EXPERIENCE WITH THE
CHLVPP/EVA HYBRID REGIMEN AS FIRST-LINE TREATMENT FOR
ADVANCED HODGKIN’S DISEASE
J.A. Radford et al., Manchester, UK

02:45 060
EXTENDED FIELD IRRADIATION DOES NOT IMPROVE SURVIVAL IN
STAGE IIIIB–IV HODGKIN’S DISEASE IN COMPLETE REMISSION OR
GOOD PARTIAL RESPONSE: A RANDOMIZED STUDY FROM THE
GELA
C. Ferné et al., Paris, France

03:00 061
DOSE ESCALATED BEACOPP CHEMOTHERAPY FOR ADVANCED
HODGKIN’S DISEASE: PROMISING RESULTS OF THE FOURTH
INTERIM ANALYSIS OF THE HD9 TRIAL
V. Diehl et al., Cologne, Germany

03:15 062
INTENSIVE THERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR
RELAPSED OR REFRACTORY HODGKIN’S DISEASE: LONG-TERM
FOLLOW-UP AND LATE EVENTS
M. Crump et al., Toronto, Canada
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ADULT LYMPHOMA IN FIRST REMISSION: RESULTS FROM A RANDOMIZED TRIAL OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION AND THE UK LYMPHOMA GROUP
G. Santini et al., Genova, Italy

A BNLI RANDOMIZED TRIAL OF CHOP VS. PACEBOM IN PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA
D.C. Linch et al., London, UK

8-WEEK VNCOP-B VERSUS 12-WEEK VNCOP-B IN ELDERLY PATIENTS WITH HIGH GRADE NON-HODGKIN'S LYMPHOMA. PRELIMINARY RESULTS FROM AN ONGOING PROSPECTIVE RANDOMIZED CLINICAL TRIAL
F. Gherlinzoni, Bologna, Italy

INTERMISSION

SESSION 8 – CLINICAL RESULTS IN LYMPHOMA II (Room A/B)
Chairpersons: R.L. Fisher and M.A. Shipp

CONSOLIDATION ABMT AFTER STANDARD CHEMOTHERAPY VS. CHVmp/BV ALONE FOR PRIMARY INTERMEDIATE HIGH GRADE NHL. A RANDOMIZED PHASE III EORTC STUDY
J.C. Kluitin-Nelemans et al., Leiden, The Netherlands

A RETROSPECTIVE ANALYSIS OF 987 PATIENTS WITH FOLLICULAR LYMPHOMA: A PREDICTIVE MODEL DEVELOPED BY THE ITALIAN LYMPHOMA INTERGROUP AND VALIDATION OF THE INTERNATIONAL PROGNOSTIC INDEX
U. Vitolo et al., Torino, Italy

THE CUP TRIAL: A RANDOMIZED STUDY ANALYZING THE EFFICACY OF HIGH DOSE THERAPY AND PURGING IN LOW-GRADE NON-HODGKIN'S LYMPHOMA
H.C. Schouten et al., Maastricht, The Netherlands

MOLECULAR RESPONSE ASSESSED BY PCR IS THE MOST IMPORTANT FACTOR PREDICTING FAILURE-FREE SURVIVAL IN INDOLENT FOLLICULAR LYMPHOMA. UPDATE OF THE MDACC SERIES
A. Lopez-Guillermo et al., Barcelona, Spain

EARLY INTERIM REPORT OF THE LYO3 RANDOMISED COOPERATIVE TRIAL OF OBSERVATION VS. CHLORAMBUCIL AFTER ANTI-HELICOBACTER THERAPY IN LOW-GRADE GASTRIC LYMPHOMA
E. Zucca et al., Bellinzona, Switzerland

MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) – LYMPHOMA ARE DISSEMINATED DISEASE IN 1/3 OF THE PATIENTS
C. Thieblemont et al., Pierre-Bénite, France

FACTORS DETERMINING FEASIBILITY AND OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR CLL
P. Dregger et al., Kiel, Germany
SESSION 9 – PEDIATRICLYMPHOMAS (Room C)
Chairperson: S.B. Murphy

04:00 073
CHILDHOOD HODGKIN’S DISEASE. EFFECTIVE MINIMAL TREATMENT
D. Jenkin et al., Riyadh, Saudi Arabia

04:15 074
CHILDHOOD HODGKIN’S DISEASE: RESULTS OF THE ITALIAN MULTICENTRIC PROTOCOL AIEOP-MH’89-CNR AND PRELIMINARY RESULTS OF THE ONGOING STUDY AIEOP-MH’96-CNR
R. Burnelli et al., Bologna, Italy

04:30 075
STAGE IV HODGKIN’S DISEASE IN CHILDREN: RESULTS OF THE UNITED KINGDOM CHILDREN’S CANCER STUDY GROUP
A. Atra et al., Sutton, UK

04:45 076
PEDIATRIC MATURE B-CELL LYMPHOMA/LEUKEMIA: INTERGROUP PATHOLOGIST CONCORDANCE WITH THE REAL CLASSIFICATION
M.A. Lones et al., Orange, USA

05:00 077
BURKITT-LIKE LYMPHOMA IS IMMUNOPHENOTYPICALLY DIFFERENT FROM BURKITT LYMPHOMA IN YOUNG PERSONS
R.E. Hutchison et al., Syracuse, USA

05:15 078
CHILDHOOD LYMPHOBLASTIC LYMPHOMA – CAN WE IMPROVE OUTCOME?
O.B. Eden, Manchester, UK

05:30 079
FAVORABLE OUTCOME FOR CHILDREN AND ADOLESCENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WITH AN INTENSIVE ALL-TYPE THERAPY WITHOUT LOCAL RADIOTHERAPY
A. Reiter et al., Hannover, Germany

05:45 080
THERAPY FOR PEDIATRIC ANAPLASTIC LARGE CELL LYMPHOMA – RESULTS FROM THERAPY-TRIAL NHL-BFM 90
K. Seidemann et al., Hannover, Germany

06:00 081
PROGNOSTIC FACTORS IN CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA: RESULTS OF THE EUROPEAN INTERGROUP STUDY
M.C. Le Deley et al., Villejuif, France

06:15 082
P80 AND VISCERAL INVOLVEMENT IN CHILDHOOD Kiil ALCL
M. Massimino et al., Milan, Italy

06:30 083
RELAPSES OF CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA: TREATMENT RESULTS IN A SERIES OF 41 CHILDREN – A REPORT FROM THE FRENCH SOCIETY OF PEDIATRIC ONCOLOGY
L. Brugières et al., Villejuif, France

SESSION 10 – CLINICAL PATHOLOGICAL CORRELATIONS (Kursaal)
Chairpersons: N.L. Harris and E. Jaffe

04:00 084
‘PARAGRANULOMA-TYPE’ – T-CELL RICH B-CELL LYMPHOMA: A REPORT OF 50 CASES
R.D. Gascoyne et al., Vancouver, Canada
EUROPEAN MANTLE CELL LYMPHOMA STUDY GROUP: PATHOLOGY, PROLIFERATION INDICES AND SURVIVAL IN 304 PATIENTS
M. Tiemann et al., Kiel, Germany

DISTRIBUTION OF VARIOUS SUBTYPES OF NON-HODGKIN'S LYMPHOMA IN INDIA: A STUDY OF 2773 LYMPHOMAS USING REAL AND WHO CLASSIFICATIONS
K.N. Naresh et al., Mumbai, India

PROLIFERATIVE ACTIVITY IN AGGRESSIVE NON-HODGKIN'S LYMPHOMAS: AN IMMUNOHISTOCHEMICAL STUDY WITH MIB-1 ANTIBODY OF 991 CASES FROM THE GELA-LNH87 TRIAL
A. Delner et al., Paris, France

IMMUNOBlastic LYMPHOMA: A SUBTYPE OF B-CELL DIFFUSE LARGE-CELL LYMPHOMA WITH DIFFERENT INITIAL FEATURES AND POOR OUTCOME
A. Lopez-Guillermo et al., Barcelona, Spain

ALK LYMPHOMAS: IMMUNODIAGNOSIS, CLINICO-PATHOLOGICAL FEATURES AND OUTCOME
B. Falini, Perugia, Italy

CD56 IS AN INDEPENDENT PROGNOSTIC FACTOR FOR T-/NULL CELL TYPE OF ANAPLASTIC LARGE CELL LYMPHOMA
R. Suzuki et al., Nagoya, Japan

ADVERSE EFFECTS OF ACTIVATED CYTOTOXIC T-LYMPHOcyTES ON THE CLINICAL OUTCOME OF NODAL ANAPLASTIC LARGE CELL LYMPHOMA
R.L. Ten Berge et al., Amsterdam, The Netherlands

γ8 T-CELL LYMPHOMAS
Ph. Gaulard et al., Créteil, France

ANGIOLymphOId HYPERplASIA WITH EOSINOPHILIA: EVIDENCE FOR A T-CELL ORIGIN
W. Kempf et al., Boston, USA

PRIMARY CUTANEOUS CD8-POSITIVE EPIDERMOTROPIC CYTOTOXIC T-CELL LYMPHOMAS: A DISTINCT CLINICO-PATHOLOGIC ENTITY WITH AN AGGRESSIVE CLINICAL BEHAVIOUR
E. Berti et al., Milan, Italy

SESSION 11 – VACCINES AND MONOCLONAL ANTIBODIES (Room A)
Chairpersons: T.A. Lister and S. Horning

CURRENT AND FUTURE ROLE OF VACCINES IN LYMPHOMA
F.K. Stevenson et al., Southampton, UK

IDIOTYPE VACCINATION AS A THERAPEUTIC STRATEGY
R. Levy, Stanford, USA
08:40 097  UNCONJUGATED MONOCLONAL ANTIBODY THERAPY OF LYMPHOMA
D.G. Maloney, Seattle, USA

09:00 098  RADIOACTIVE MONOCLONAL ANTIBODIES
M.S. Kaminski, Ann Arbor, USA

09:20 099  SUBSEQUENT THERAPY CAN BE ADMINISTERED FOLLOWING TREATMENT WITH IODINE-131 ANTI-B1 ANTIBODY IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
N.K. Valente et al., Palo Alto, USA

09:35 100  AUTOLOGOUS LYMPHOCYTES AS VECTORS TO TARGET THERAPY LOW GRADE NHL AND CLL
R.A. Cowan et al., Manchester, UK

09:50 101  IMMUNOTHERAPY OF MANTLE CELL LYMPHOMA WITH RITUXIMAB: DURATION OF RESPONSE & ANALYSIS OF FACTORS ASSOCIATED WITH RESPONSE
J.M. Foran et al., London, UK

10:05 102  THE EFFECT OF RITUXIMAB ON PATIENTS WITH FOLLICULAR AND MANTLE CELL LYMPHOMA
M. Ghielmini et al., Bellinzona, Switzerland

10:20 103  EARLY MOLECULAR RESPONSES IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA PATIENTS WITH RITUXIMAB AS FIRST LINE TREATMENT
G. Salles et al., Pierre-Bénite, France

10:35 104  INTERFERON-? INDUCES CD20 EXPRESSION ON MULTIPLE MYELOMA PATIENT AND HEALTHY DONOR PLASMA CELLS AND B-CELLS AND AUGMENTS BINDING OF RITUXIMAB (RITUXAN) TO MM PLASMA CELLS
S.P. Treon et al., Boston, USA

10:50  CLOSING REMARKS
J.O. Armitage, Omaha, USA

11:15  CLOSE

08:00–10:45 a.m.  SESSION 12 – FUTURE DEVELOPMENTS (Room B)
Chairmen: J.O. Armitage and M. Gianni

08:00 105  POLYAMINE ANALOGUE THERAPY WITH DIETHYLHOMOSPERMINE FOR HIV-ASSOCIATED NON-HODGKIN'S LYMPHOMA: TARGETING PROLIFERATING MACROPHAGES
L.D. Kaplan et al., San Francisco, USA

08:15 106  KI-3(SCFV)-ETA', A NEW RECOMBINANT ANTI-CD30 IMMUNOTOXIN FOR THE TREATMENT OF HODGKIN LYMPHOMA CELLS
B. Matthey et al., Cologne, Germany

08:30 107  LIPOSOMAL VINCRISTINE IN RELAPSED NHL: EARLY RESULTS
A.H. Sarris et al., Houston, USA
PBPC MOBILIZATION, HARVEST AND REINFUSION FOR CHEMOTHERAPY INTENSIFICATION IN ELDERLY NON-HODGKIN'S LYMPHOMA PATIENTS
C. Tarella et al., Torino, Italy

FEASIBILITY OF TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN VERY UNFAVORABLE RELAPSE FROM HODGKIN'S DISEASE
P. Brice et al., Paris, France

ALLOGENEIC TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: MOLECULAR REMISSIONS AND EVIDENCE OF GRAFT-VERSUS-MALIGNANCY
L.F. Khouri et al., Houston, USA

ALLOGENEIC BONE MARROW TRANSPLANTATION FOR LOW GRADE LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
C.L. Toze et al., Vancouver, Canada

ALLOGENEIC BONE MARROW AND BLOOD CELL TRANSPLANTS TO TREAT PATIENTS WITH LYMPHOMA
J.O. Armitage, Omaha, USA

ANTISENSE OLIGONUCLEOTIDE THERAPY
F.E. Cotter et al., London, UK

GENE THERAPY OF LEUKEMIAS AND LYMPHOMAS
T.J. Kipps, La Jolla, USA

END OF SESSION

CLOSING REMARKS (Room A)
J.O. Armitage, Omaha, USA